Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

231.19
-0.2000-0.09%
Post-market: 231.190.00000.00%16:15 EDT
Volume:578.90K
Turnover:134.40M
Market Cap:15.01B
PE:15.80
High:235.54
Open:229.62
Low:227.00
Close:231.39
52wk High:266.38
52wk Low:128.80
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.71
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.13
PE(LYR):-39.59

Loading ...

Jazz Pharmaceuticals (JAZZ) Stock May Be Undervalued As FDA Cancer Approval Lands

Simply Wall St.
·
Aug 27

Jazz Pharmaceuticals Prices Upsized $1.1 Billion Senior Notes Offering

MT Newswires Live
·
Aug 27

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 27

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT Newswires Live
·
Aug 27

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 27

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals price target raised to $281 from $264 at Truist

TIPRANKS
·
Aug 26

Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes Due 2032 and Concurrent Ordinary Share Repurchases

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Initial Purchasers May Buy up to $150 Mln Additional Notes

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Expects to Repurchase up to $225 Mln of Ordinary Shares Concurrently

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Net Proceeds from Offering Expected to be Used for General Corporate Purposes

THOMSON REUTERS
·
Aug 26

Piper Sandler Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 26

RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Highlights Ziihera Launch, Targets $3-$5 Billion Zanidatamab Peak Sales Opportunity

Reuters
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)

TIPRANKS
·
Aug 26

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Reuters
·
Aug 26

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $281 from $264

THOMSON REUTERS
·
Aug 26

Jazz Pharma Says FDA Approves Ziihera Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

Reuters
·
Aug 25

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Includes Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 25